Company intelligence / Profile preview

Avecia Biologics

Milford, Massachusetts, United Statesavecia.com ↗

Ownership: Private
Development stage: Commercial

Overview

Nitto Avecia provides contract development and manufacturing services specializing in oligonucleotide therapeutics. The company has manufactured over 1,200 unique oligonucleotide sequences and supports pharmaceutical innovators from early development through commercial production. Its historical biologics division was a leader in microbial-derived biopharmaceuticals before being acquired by Merck in the UK.

Therapeutic areas: OncologyRare DiseasesOtherCardiovascularNeurology
Modalities: Oligonucleotide therapyBiologic
Industry: Contract Manufacturing Organization

Partnerships

Multiple pharmaceutical and biotech companies as clients; specific partnerships not disclosed publicly.

Beyond the preview

Go deeper on Avecia Biologics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Avecia Biologics.

Explore the full profile